Activation of RIPK2, as a downstream molecule of the NOD receptor and TOLL receptor, can promote the MAPK/NF-κB signaling pathway and to promote intestinal inflammation in IBD, whereas RIPK2 knockdown can attenuate this effect [43–45]. Here, NFKB1 is linked to inflammatory bowel disease.